secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001558370-24-015705
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics reports Q3 net loss of $0.17/share; plans Phase 1b start for GT-02287 by year-end
--------------------------------------------------------------------------------

- Net loss per share improved to $0.17 from $0.37 in Q3 2023; R&D spend rose to $2.6M.
- Cash and marketable securities $12M as of Sept 30, 2024, down from $16.8M at Dec 31, 2023.
- Phase 1 MAD results showed 53% increase in GCase activity; safety and tolerability confirmed.
- Initiation of Phase 1b trial in Parkinson's patients expected by end of Q4 2024.
- Pre-IND meeting with FDA planned before end of 2024 to support Phase 2 expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000155837024015705/0001558370-24-015705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000155837024015705/ganx-20241114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer